Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Panel Supports Roche HPV Assay To Replace Pap As Primary Cervical Cancer Screen

This article was originally published in The Gray Sheet

Executive Summary

The Microbiology Devices Panel provided unanimous support Roche’s submission to upgrade labeling for it cobas HPV test as a first-line, primary screen for cervical cancer.


Related Content

Roche’s HPV Test Approved As First-Line Cervical Cancer Screen
HPV Testing Evidence Examined In Cervical Cancer Screening Guidelines
Roche Ramps Up Sales Force For U.S. Launch Of HPV Test


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts